Start for free
Start for free
DC

Duquesne Capital Management

North America, New York, United States, New York

Description

Duquesne Capital Management provides its services to high net worth individuals and institutions.

Investor Profile

Duquesne Capital Management has made 7 investments, with 0 in the past 12 months and 29% as lead.

Stage Focus

  • Series C (29%)
  • Series D (29%)
  • Series Unknown (14%)
  • Series B (14%)
  • Series A (14%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Biopharma
  • Medical
  • Health Care
  • Life Science
  • Therapeutics
  • Delivery
  • Digital Media
  • Mobile
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Duquesne Capital Management frequently co-invest with?

BM
BioFund Management
Europe, Southern Finland, Finland, Helsinki
Co-Investments: 1
Goldman Sachs
Goldman Sachs
North America, New York, United States, New York
Co-Investments: 1
Adage Capital Management
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Daiwa SMBC Capital
Daiwa SMBC Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
SF
Schusterman Family Investments
North America, New York, United States, New York
Co-Investments: 2
AC
Apothecary Capital
North America, Illinois, United States, Chicago
Co-Investments: 1
CB
Co-Investments: 1
Galleon Group
Galleon Group
North America, New York, United States, New York
Co-Investments: 2
Astellas Pharma
Astellas Pharma
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Brookside Capital
Brookside Capital
North America, California, United States, San Francisco
Co-Investments: 1

What are some of recent deals done by Duquesne Capital Management?

Ratio Therapeutics

Boston, Massachusetts, United States

Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

BiopharmaBiotechnologyLife ScienceMedicalPharmaceutical
Series BJan 17, 2024
Amount Raised: $50,000,000
Ratio Therapeutics

Boston, Massachusetts, United States

Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

BiopharmaBiotechnologyLife ScienceMedicalPharmaceutical
Series AFeb 1, 2023
Amount Raised: $20,000,000
Agensys

Santa Monica, California, United States

Agensys offers products to treat various tumors as well as prostate, pancreatic and bladder cancers.

BiotechnologyHealth DiagnosticsPharmaceutical
Series DJul 12, 2007
Amount Raised: $41,300,000
Dilithium Networks

Petaluma, California, United States

Dilithium offered high-quality multimedia delivery over mobile and broadband networks to any device.

DeliveryDigital MediaMobile
Series DJul 3, 2007
Amount Raised: $33,000,000
BPL Global

Canonsburg, Pennsylvania, United States

BPL Global is a smart grid technology company that provides software solutions and services to electric utilities.

EnergyInternet of ThingsSoftware
Series CFeb 15, 2007
Amount Raised: $26,000,000
FibroGen

San Francisco, California, United States

FibroGen uses its expertise in CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.

BiopharmaBiotechnologyHealth CareTherapeutics
Series UnknownFeb 17, 2005
Amount Raised: $100,000,000
Synta Pharmaceuticals

Lexington, Massachusetts, United States

Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.

BiotechnologyHealth CareMedicalPharmaceutical
Series CJan 14, 2004
Amount Raised: $50,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator